Jpmorgan Chase & CO Novo Cure LTD Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Novo Cure LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 217,657 shares of NVCR stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
217,657
Previous 367,702
40.81%
Holding current value
$2.88 Million
Previous $11 Million
64.61%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding NVCR
# of Institutions
284Shares Held
77.5MCall Options Held
943KPut Options Held
155K-
Black Rock Inc. New York, NY12.1MShares$161 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$142 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.9MShares$91.4 Million9.53% of portfolio
-
Capital World Investors Los Angeles, CA6.38MShares$84.5 Million0.02% of portfolio
-
State Street Corp Boston, MA2.68MShares$35.5 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.39B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...